Phathom Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-…

Biotechnology
US, Florham Park [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Phathom Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of PHAT's Analysis
CIK: 1783183 CUSIP: 71722W107 ISIN: US71722W1071 LEI: - UEI: -
Secondary Listings
PHAT has no secondary listings inside our databases.